Abstract 14158: Impact of Statin Following Endovascular Aneurysm Repair in Patients With Abdominal Aortic Aneurysm
Introduction: Endovascular aneurysm repair (EVAR) has been an established treatment for abdominal aortic aneurysm (AAA). Although statin use has been shown associated with better long-term survival following open AAA surgery, its impact on EVAR has not been systematically explored.
Methods: We retrospectively analyzed a multicenter database of 368 consecutive patients (age, 76 ± 8 years; 84% male) undergoing EVAR for AAA between November 2006 and December 2013. The outcome measure was overall survival following EVAR. Independent predictor associated with the outcome was assessed by Cox proportional hazard regression model. Furthermore, the association between the statin use and the outcome was assessed.
Results: During the follow-up of 30 ± 20 months, 38 patients died from cardiovascular disease (33%), cancer (23%) or infection (23%). Survival rate was 96% and 81% at 1 and 5 years, respectively. In Cox regression analysis, statin use (in 213 AAA patients, 58%) was negatively associated with the mortality [HR, 0.34; P = 0.002]. There was a significant interaction effect between statin and preoperative aneurysm size. The adjusted hazard ratio of statin for mortality was 0.19 (95% confidence interval (CI): 0.08 to 0.48, p < 0.001) in patients with preoperative aneurysm size < 55 mm, whereas it was 1.00 (95% CI: 0.31 to 3.19, p = 1.000) in those with preoperative aneurysm size ≥ 55 mm. (Figure)
Conclusions: In this retrospective study, statin use was associated with a better long-term survival following EVAR for AAA, particularly in those with preoperative diameter <55mm.
Author Disclosures: K. Nanto: None. O. Iida: None. M. Fujita: None. M. Masuda: None. S. Okamoto: None. T. Ishihara: None. T. Shiraki: None. T. Kanda: None. A. Sunaga: None. T. Tsujimura: None. S. Okuno: None. K. Yanaka: None. Y. Matsuda: None. T. Ohashi: None. J. Tazaki: None. M. Uematsu: None.
- © 2015 by American Heart Association, Inc.